Analyst consensus rating
Amylyx Pharmaceuticals Analyst Rating: Strong Buy
AMLX is rated Strong Buy by 11 analysts with a $42.18 target. As of 2026-08-20.
Direct answer
Amylyx Pharmaceuticals's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $42.18.
Forecast evidence checked August 20, 2026.
Get free Amylyx Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $39.66
- Average price target
- $42.18
- High price target
- $55.00
- Low price target
- $20.00
- Low target gap
- -49.6%
- Target upside
- +6.4%
- High target gap
- +38.7%
- Target range width
- 88.3%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- August 20, 2026
- Valid through
- August 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $42.18.
How far are Amylyx Pharmaceuticals's low and high targets from the recorded price?
The low target implies -49.6%, while the high target implies +38.7%.
How many analysts are included in Amylyx Pharmaceuticals's consensus?
The verified consensus includes 11 analysts.
How is Amylyx Pharmaceuticals's target upside or downside calculated?
The average target of $42.18 is divided by the recorded price of $39.66, then one is subtracted to produce +6.4%. This does not guarantee a future return.
When was Amylyx Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-20. The dataset is valid through 2026-08-27.